Medicxi Launches Alys Pharmaceuticals in $100m Seed Funding

Medicxi launches Alys Pharmaceuticals with $100m funding to develop groundbreaking therapies in immunodermatology. The company aims to address unmet needs in treating dermatitis associated with radiotherapy and other conditions. Alys Pharmaceuticals has a strong team of experts and an ambitious target of delivering multiple proof-of-concept readouts by 2026. With its financial backing and diverse portfolio, the company is well-positioned for success.